Does Pathology in Locus Coeruleus Trigger AD?
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
July 01, 2019 - November 30, 2021
Grant ID
A2019307S
Goals
The locus coeruleus (LC) of the brain is important for sleep and memory, but it’s unclear if accumulation of tau in its neurons is an early sign of Alzheimer’s disease. By studying the electrical activity of LC neurons in mice, we will determine if tau prevents LC to function normally and causes sleep and memory problems. In addition, we will manipulate the activity of the LC neurons in order to restore its function and reverse sleep and memory impairment.
Summary
Tau, one of the hallmark pathologies of AD, accumulates in the locus coeruleus of 20-year-old healthy adults, and yet, its consequences remain unknown. To mimic tau accumulation in the LC, we will extract tau from human AD brains and inject it into the LC of mice. We will then monitor sleep and test memory determine if tau impacts sleep prior to the onset of AD-like cognitive symptoms. A major innovation of this project is to be able to predict the onset of AD. The study pioneers the use of multi-region electrodes to probe brain regions involved in sleep and memory combined with machine learning approach to predict early symptoms of AD. Additionally, the project aims to reverse LC dysfunction using optogenetic tools.
The results of this study will inform and help predict if sleep disturbances in young adults are important predictors Alzheimer’s disease.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD